17 Hydroxyprogesterone for the prevention of preterm delivery

Obstetrics and Gynecology

Volumn 105, Issue 5 I, 2005, Pages 1128-1135

  Meis, Paul J ^a  

^a Dept of Obstetrics and Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROGESTERONE; PROGESTERONE;

CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; GESTATION PERIOD; HIGH RISK POPULATION; HUMAN; META ANALYSIS; NONHUMAN; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; SECOND TRIMESTER PREGNANCY; SIDE EFFECT; TERATOGENESIS; TREATMENT INDICATION; UTERINE CERVIX DISEASE;

17-ALPHA-HYDROXYPROGESTERONE; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GESTATIONAL AGE; HUMANS; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY, HIGH-RISK; PREGNANCY, MULTIPLE; PREMATURE BIRTH; PRENATAL CARE; RANDOMIZED CONTROLLED TRIALS; REFERENCE VALUES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 17644375880     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000160432.95395.8f     Document Type: Review

References (55)

1. Papiernik E. Double blind study of an agent to prevent pre-term delivery among women at increased risk. In: Edition Schering, Serie IV, fiche 3. 1970;65-8.
2. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate [published erratum appears in N Engl J Med. 2003;349:1299]. N Engl J Med 2003;348:2379-85.
3. da Fonseca EB, Bittar RE, Carvalho MHB, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous pre-term birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419-24.
4. Paneth NS. The Problem of Low Birth Weight. Future Child 1995;5:19-34
5. Mattison DR, Damus K, Fiore E, Petrini J, Alter C. Preterm delivery: a public health perspective. Paediatr Perinat Epidemiol 2001;15(suppl 2):7-16.
6. Agency of Heathcare Research and Quality. Overview of the HCUP Nationwide Inpatient Sample 2001. Available at: http://www.hcup-us.ahrq.gov/nisoverview. jsp. Retrieved March 2, 2005.
7. Gyetvai D, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999;94:869-77.
8. Harger JH. Cerclage and cervical insufficiency: an evidence-based analysis. Obstet Gynecol 2002;100:1313-27.
9. Carey JC, Klebanoff MA, Hauth JC, Hillier SL, Thom EA, Ernest JM, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med 2000;342:534-40.
10. Klebanoff MA, Carey JC, Hauth JC, Hillier SL, Nugent RP, Thom EA, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001;345:487-93.
11. Creasy RK. Preterm birth prevention: where are we? Am J Obstet Gynecol 1993;168:1223-30.
12. Rebar RW, Cedars MI. Hypergonadotropic forms of amenorrhea in young women. Endocrinol Metab Clin North Am 1992;21:173-91.
13. Stites DP, Siiteri PK. Steroids as immunosuppressants in pregnancy. Immunol Rev 1983;75:117-38.
14. Siiteri PK, Seron-Ferre M. Some new thoughts on the feto-placental unit and parturition in primates. In: Novy MJ, Reskko JA, editors. Fetal endocrinology. New York (NY): Academic Press; 1981. p. 1-34.
15. Garfield RE, Dannan MS, Daniel EE. Gap junction formation in myometrium: control by estrogens, progesterone, and prostaglandins. Am J Physiol 1980;238:C81-9.
16. Challis JRG. Sharp increase in free circulating oestrogens immediately before parturition in sheep. Nature 1971;229:208.
17. Csapo AI. Progesterone block. Am J Anat 1956;98:273-91.
18. Cousins LM, Hobel CJ, Chang RJ, Okada DM, Marshall JR. Serum progesterone and estradiol-17b levels in premature and term labor. Am J Obstet Gynecol 1977;127: 612-5.
19. Johnson JWC, Lee PA, Zachary AS, Calhoun S, Migeon CJ. High-risk prematurity-progestin treatment and steroid studies. Obstet Gynecol 1979;54:412-8.
20. Mitchell B, Cruickshank B, McLain, Challis J. Local modulation of progesterone production in human fetal membranes. J Clin Endocrinol Metab 1982;55:1237-9.
21. Romero R, Scoccia B, Mazor M, Wu YK, Benveniste R. Evidence for a local change in the progesterone/estrogen ratio in human parturition at term. Am J Obstet Gynecol 1988;159:657-60.
22. Frydman R, LeLaidier C, Baton-Saint-Mleux C, Fernandez H, Vial M, Bourget P. Labor induction in women at term with mifepristone (RU 486): a double-blind, randomized, placebo-controlled study. Obstet Gynecol 1992;80:972-5.
23. LeLaidier C, Baton C, Benifla JL, Fernandez H, Bourget P, Frydman R. Mifepristone for labour induction after previous caesarean section. Br J Obstet Gynaecol 1994;101:501-3.
24. Chwalisz K, Fahrenholz F, Hackenbery M, Hackenberg M, Garfield R, Elger W. The progesterone antagonist onapristone increases the effectiveness of oxytocin to produce delivery without changing the myometrial oxytocin receptor concentrations. Am J Obstet Gynecol 1991;165:1760-70.
25. Johnson JWC, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975;293:675-80.
26. Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynaecol 1989;96:265-74.
27. Keirse MJNC. Progesterone administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990;97:149-54.
28. Hartikainen-Sorri AL, Kauppila A, Tuimala R. Inefficacy of 17 alpha hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980;56:692-5.
29. Hauth JC, Gilstrap LC 3rd, Brekken AL, Hauth JM. The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol 1983;146:187-90.
30. Tulchinsky D, Simmer H. Sources of plasma 17alpha-hydroxyprogesterone in human pregnancy. J Clin Endocrinol Metab 1972;35:799-808.
31. Kessler W, Borman A. Some biological activities of certain progestogens.I. 17 alpha-hydroxyprogesterone 17-n-caproate.Ann N Y Acad Sci 1958;71:486-93.
32. Johnstone EE, Franklin RR. Assay of progestins for fetal virilizing properties using the mouse. Obstet Gynecol 1964;23:359-62.
33. Courtney KD, Valerio DA. Teratology in the Macaca mulatta. Teratology 1968;1:163-72.
34. Carbone JP, Brent RL. Genital and nongenital teratogenesis of prenatal progesterone therapy: the effects of 17alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6L mouse. Am J Obstet Gynecol 1993;169:1292-8.
35. See miller RE, Nelson GW, Johnson CK. Evaluation of teratogenic potential of Delalutin, (17 alpha-hydroxyprogesterone caproate) in mice. Teratology 1983;28:201-8.
36. Varma T, Morsman J. Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexonate) in early pregnancy. Int J Gnyaecol Obstet 1982;20:13-7.
37. Michaelis J, Michaelis H, Gluck E, Keller S. Prospective studies of suspected association between certain drugs administered in early pregnancy and congenital malformations. Teratology 1983;27:57-64.
38. Resseguie LJ, Hick JF, Bruen JA, Noller KL, O'Fallon WM, Kurland LT. Congenital malformations among offspring exposed in utero to progestins, Olmstead County, Minnesota 1936-1974. Fertil Steril 1985;43:514-9.
39. Check JH, Rankin A, Teichman M. The risk of fetal anomalies as a result of progesterone therapy during pregnancy. Fertil Steril 1986;45:575-7.
40. Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol 1985;65:775-80.
41. Kester PA. Effects of prenatally administered 17 alpha- hydroxyprogesterone caproate in adolescent males. Arch Sex Behav 1984;13:441-55.
42. Schardein JL. Congenital abnormalities and hormones during pregnancy: a clinical review. Teratology 1980;22:251-70.
43. Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol 1995;85:141-9.
44. REPROTOX 1997 Healthcare Series. Vol 92. Greenwood Village (CO): Micromedex Inc; 1997.
45. LeVine L. Habitual abortion: a controlled clinical study of pregestational therapy. West J Surg Obstet Gynecol 1964;72:30-6.
46. Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I, et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 1985;151:574-7.
47. Sherman AI. Hormonal therapy for control of the incompetent os of pregnancy. Obstet Gynecol 1966;28:198-205.
48. Elovitz M, Wang Z. Medroxyprogesterone acetate, but not progesterone, protects against inflammation-induced parturition and intrauterine fetal demise. Am J Obstet Gynecol 2004;190:693-701.
49. Hobel CJ, Ross MG, Bemis RL, Bragonier JR, Nessim S, Sandhu M, et al. The West Los Angeles Preterm Birth Prevention Project. I. Program impact on high-risk women. Am J Obstet Gynecol 1994;170:54-62.
50. Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, et al. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol 2005;105:267-72.
51. Fuchs F, Stakemann G. Treatment of threatened premature labor with large doses of progesterone. Am J Obstet Gynecol 1960;79:172-6.
52. Kauppila A, Hartikainen-Sorri AL, Janne O, Tuimala R, Jarvinen PA. Suppression of threatened premature labor by administration of cortisol and 17 alpha-hydroxyprogesterone caproate: a comparison with ritodrine. Am J Obstet Gynecol 1980;138:404-8.
53. Erny R, Pigne A, Prouvost C, Gamerre M, Malet C, Serment H, et al. The effects of oral administration of progesterone for premature labor. Am J Obstet Gynecol 1986;154:525-9.
54. Noblot G, Audra P, Dargent D, Faguer B, Mellier G, et al. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol 1991;40:203-9.
55. Brenner WE, Hendricks CH. Effect of medroxyprogesterone acetate upon the duration and characteristics of human gestation and labor. Am J Obstet Gynecol 1962;83:1094-8.